HIV-1 疫苗的设计与评估。
The design and evaluation of HIV-1 vaccines.
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3005, USA.
出版信息
AIDS. 2012 Jun 19;26(10):1293-302. doi: 10.1097/QAD.0b013e32835474d2.
Abstract
There is renewed optimism that the goal of developing a highly effective AIDS vaccine is attainable. The HIV-1 vaccine field has seen its first trial of a vaccine candidate that prevents infection. Although modest in efficacy, this finding, along with the recent discovery that the human immune system can produce broadly neutralizing antibodies capable of inhibiting greater than 90% of circulating viruses, provides a guide for the rational design of vaccines and protection by passive immunization. Together, these findings will help shape the next generation of HIV vaccines.
摘要
人们对研发高效艾滋病疫苗的目标再次感到乐观。HIV-1 疫苗领域已经进行了首次疫苗候选物临床试验，该疫苗可以预防感染。尽管效果有限，但这一发现，以及最近发现人类免疫系统可以产生广泛中和抗体，能够抑制超过 90%的循环病毒，为疫苗的合理设计和被动免疫保护提供了指导。这些发现将共同帮助塑造下一代 HIV 疫苗。
相似文献
1
The design and evaluation of HIV-1 vaccines.HIV-1 疫苗的设计与评估。
AIDS. 2012 Jun 19;26(10):1293-302. doi: 10.1097/QAD.0b013e32835474d2.
2
HIV vaccine efficacy trials: towards the future of HIV prevention.HIV疫苗效力试验：迈向HIV预防的未来
Infect Dis Clin North Am. 2007 Mar;21(1):201-17, x. doi: 10.1016/j.idc.2007.01.006.
3
No acquisition: a new ambition for HIV vaccine development?无获得：HIV 疫苗研发的新目标？
Curr Opin Virol. 2011 Oct;1(4):246-53. doi: 10.1016/j.coviro.2011.07.005.
4
The HIV vaccine pipeline, from preclinical to phase III.从临床前到三期的HIV疫苗研发进程。
AIDS. 2001;15 Suppl 5:S147-58. doi: 10.1097/00002030-200100005-00018.
5
Human immunodeficiency virus vaccines.人类免疫缺陷病毒疫苗
Infect Dis Clin North Am. 2014 Dec;28(4):615-31. doi: 10.1016/j.idc.2014.08.004. Epub 2014 Oct 5.
6
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.用于 HIV-1 预防的疫苗和广泛中和抗体。
Annu Rev Immunol. 2020 Apr 26;38:673-703. doi: 10.1146/annurev-immunol-080219-023629.
7
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.设计引发 HIV-1 广谱中和抗体的疫苗的合理性。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278.
8
Public health. A sound rationale needed for phase III HIV-1 vaccine trials.公共卫生。HIV-1疫苗三期试验需要合理依据。
Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620.
9
Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.评估1型人类免疫缺陷病毒疫苗效力试验中的免疫相关因素：RV144试验可能带来的启示。
AIDS Res Hum Retroviruses. 2012 Apr;28(4):400-4. doi: 10.1089/aid.2011.0240. Epub 2011 Sep 27.
10
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.广谱中和抗体与 HIV-1 疫苗的研发：万里长征第一步。
Nat Rev Immunol. 2013 Sep;13(9):693-701. doi: 10.1038/nri3516.
引用本文的文献
1
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120.基于免疫信息学的针对HIV-1 gp120的多表位mRNA疫苗的设计与评估
Front Immunol. 2025 May 13;16:1480025. doi: 10.3389/fimmu.2025.1480025. eCollection 2025.
2
Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding.当代 HIV-1 共识Env 与人工智能辅助重新设计的超变环促进抗体结合。
Nat Commun. 2024 May 9;15(1):3924. doi: 10.1038/s41467-024-48139-x.
3
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.B 细胞与 HIV-1 始祖病毒包膜的结合可预测广泛中和抗体的产生。
Cell Host Microbe. 2021 Apr 14;29(4):564-578.e9. doi: 10.1016/j.chom.2021.01.016. Epub 2021 Mar 3.
4
Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes.编码CIITA基因的禽痘病毒重组体增加了内源性MHC-II以及禽痘病毒Gag/Pro和Env SIV转基因的表达。
PLoS One. 2018 Jan 31;13(1):e0190869. doi: 10.1371/journal.pone.0190869. eCollection 2018.
5
Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City.纽约市年轻黑人男男性行为者和跨性别女性参与艾滋病毒疫苗及预防研究的障碍与促进因素
PLoS One. 2017 Jul 19;12(7):e0181702. doi: 10.1371/journal.pone.0181702. eCollection 2017.
6
Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.通过初免-加强免疫在兔体内诱导异源2级HIV-1中和及交叉反应性V1/V2特异性抗体
J Virol. 2016 Sep 12;90(19):8644-60. doi: 10.1128/JVI.00853-16. Print 2016 Oct 1.
7
Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.人免疫缺陷病毒1型表面抗原上的N-连接聚糖在调节病毒对针对受体和共受体结合位点的广泛中和抗体敏感性方面的保守作用。
J Virol. 2015 Oct 28;90(2):829-41. doi: 10.1128/JVI.02321-15. Print 2016 Jan 15.
8
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.采用简化的皮内注射HIV-1 DNA疫苗方案进行初免，随后用重组HIV-1 MVA疫苗进行加强免疫是安全且具有免疫原性的：一项IIa期随机临床试验。
PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015.
9
An infectious molecular clone in early infection with HIV-1 subtype CRF01_AE strains: construction and biological properties.HIV-1 CRF01_AE亚型毒株早期感染的感染性分子克隆：构建及生物学特性
Mol Biol Rep. 2015 Feb;42(2):329-36. doi: 10.1007/s11033-014-3754-9. Epub 2014 Nov 6.
10
Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition.介导病毒抑制的HIV-1抗原特异性CD8 + T细胞中细胞因子基因表达的转录和转录后调控。
J Virol. 2014 Sep 1;88(17):9514-28. doi: 10.1128/JVI.00802-14. Epub 2014 Jun 4.
本文引用的文献
1
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
2
The Antibody Response against HIV-1.HIV-1 的抗体反应。
Cold Spring Harb Perspect Med. 2012 Jan;2(1):a007039. doi: 10.1101/cshperspect.a007039.
3
Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.鉴定可减轻金黄色葡萄球菌皮肤坏死严重程度并显示亲和力与效力之间相关性的抗α毒素单克隆抗体。
Clin Vaccine Immunol. 2012 Mar;19(3):377-85. doi: 10.1128/CVI.05589-11. Epub 2012 Jan 11.
4
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.设计引发 HIV-1 广谱中和抗体的疫苗的合理性。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278.
5
Vaccine design for CD8 T lymphocyte responses.针对 CD8 T 淋巴细胞反应的疫苗设计。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007252. doi: 10.1101/cshperspect.a007252.
6
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.疫苗对恒河猴中中和耐药性 SIV 挑战获得的保护作用。
Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.
7
Antibody-based protection against HIV infection by vectored immunoprophylaxis.基于抗体的载体免疫预防保护 HIV 感染。
Nature. 2011 Nov 30;481(7379):81-4. doi: 10.1038/nature10660.
8
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.HIV-1 gp120 V1/V2 结构域与广谱中和抗体 PG9 结合。
Nature. 2011 Nov 23;480(7377):336-43. doi: 10.1038/nature10696.
9
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.一种强效且广谱的中和抗体可识别并穿透 HIV 聚糖盾牌。
Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13.
10
Moving ahead an HIV vaccine: use both arms to beat HIV.推进艾滋病疫苗研发：双臂并用抗击艾滋病毒。
Nat Med. 2011 Oct 11;17(10):1194-5. doi: 10.1038/nm.2529.
Zotero 插件